AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Zoetis Inc (NYSE:ZTS)
177 USD
+1.300 0.740%Sponsored Reports
Loading...
| Previous Close (in USD) | 175.7 |
|---|---|
| Change | +1.300 0.740% |
| 52 W H/L (in USD) | 201.920/140.241 |
| EBITDA (in USD) | 3473M |
| PE Ratio | 40.18 |
| Volume | 1621681 |
| Diluted Eps TTM | 4.90 |
| Total Assets (in USD) | 14925M |
|---|---|
| Total Liabilities (in USD) | 10522M |
| Revenue TTM (in USD) | 8371M |
| Cash (in USD) | 3577M |
| Market Cap (in USD) | 90,399.539 M |
| Revenue Per Share TTM | 18.087 |
| Gross Profit TTM (in USD) | 5634M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Zoetis Inc
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Employees: 13800
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Ms. Kristin C. Peck | CEO & Director | 1971 |
| 2. | Mr. Wetteny N. Joseph | Exec. VP & CFO | 1972 |
| 3. | Ms. Heidi C. Chen | Exec. VP, Gen. Counsel, Corp. Sec. & Bus. Lead of Human Health Diagnostics | 1967 |
| 4. | Mr. Glenn C. David | Exec. VP & Group Pres of U.S. Operations, Global Diagnostics and BioDevices | 1972 |
| 5. | Ms. Roxanne Lagano | Exec. VP and Chief HR Officer & Global Operations | 1965 |
| 6. | Ms. Wafaa Mamilli | EVP, Chief Digital & Tech. Officer, Group Pres for China, Brazil and Preci. Animal Health | 1967 |
| 7. | Mr. Steven Frank | VP of Investor Relations | NA |
| 8. | Mr. William Price | VP & Chief Communications Officer | NA |
| 9. | Dr. Robert J. Polzer Ph.D. | Exec. VP and Pres of R&D | 1969 |
| 10. | Ms. Jeannette Ferran Astorga | Exec. VP of Corp. Affairs & Communications and Chief Sustainability Officer | 1975 |
Peers
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
MKKGY
Merck KGaA ADR |
+0.260 0.875% | 29.88 | 21.250 | 14.925 | 3.099 | 2.143 | 3.605 | 12.978 |
|
MKGAF
MERCK Kommanditgesellschaft auf Aktien |
+1.000 0.669% | 150.5 | 21.730 | 14.948 | 3.159 | 2.147 | 3.562 | 12.822 |
|
TAK
Takeda Pharmaceutical Co Ltd ADR |
+0.135 1.005% | 13.49 | 32.670 | 11.534 | 0.011 | 0.874 | 0.018 | 0.069 |
|
TKPHF
Takeda Pharmaceutical Co. Ltd. |
0.000 0.000% | 27.2 | 32.600 | 11.588 | 0.011 | 0.878 | 0.018 | 0.069 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | 2656M | 2488M | 1996M | 1801M | 1690M |
| Minority Interest | 3M | -3M | -2M | 4M | -4M |
| Net Income | 2114M | 2037M | 1638M | 1500M | 1428M |
| Selling General Administrative | 2009M | 2001M | 1726M | 1638M | 1484M |
| Gross Profit | 5626M | 5473M | 4618M | 4268M | 3914M |
| Reconciled Depreciation | 465M | 161M | 441M | 412M | 308M |
| Ebit | 2888M | 2755M | 2288M | 2075M | 1964M |
| Ebitda | 3038M | 2916M | 2729M | 2230M | 2081M |
| Depreciation And Amortization | 150M | 161M | 441M | 155M | 117M |
| Operating Income | 2888M | 2755M | 2288M | 2075M | 1881M |
| Other Operating Expenses | 5152M | 4973M | 4406M | 4242M | 3944M |
| Interest Expense | 221M | 224M | 231M | 223M | 206M |
| Tax Provision | 545M | 454M | 360M | 301M | 266M |
| Interest Income | 50M | 6M | 12M | 37M | 31M |
| Net Interest Income | -171M | -224M | -219M | -186M | -175M |
| Income Tax Expense | 545M | 454M | 360M | 301M | 266M |
| Total Revenue | 8080M | 7776M | 6675M | 6260M | 5825M |
| Total Operating Expenses | 2698M | 2670M | 2349M | 2250M | 2033M |
| Cost Of Revenue | 2454M | 2303M | 2057M | 1992M | 1911M |
| Total Other Income Expense Net | -232M | -267M | -292M | -274M | 15M |
| Net Income From Continuing Ops | 2111M | 2034M | 1636M | 1500M | 1424M |
| Net Income Applicable To Common Shares | 2114M | 2037M | 1638M | 1500M | 1428M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Total Assets | 14925M | 13900M | 13609M | 11545M | 10777M |
| Intangible Assets | 1380M | 1474M | 1710M | 1890M | 2046M |
| Other Current Assets | 365M | 389M | 366M | 318M | 271M |
| Total Liab | 10522M | 9356M | 9836M | 8837M | 8592M |
| Total Stockholder Equity | 4405M | 4543M | 3769M | 2708M | 2185M |
| Other Current Liab | 1410M | 1361M | 93M | 55M | 866M |
| Common Stock | 5M | 5M | 5M | 5M | 5M |
| Capital Stock | 5M | 5M | 5M | 5M | 5M |
| Retained Earnings | 8668M | 7186M | 5659M | 4427M | 3270M |
| Good Will | 2746M | 2682M | 2694M | 2592M | 2519M |
| Other Assets | 320M | 211M | 392M | 160M | 147M |
| Cash | 3577M | 3482M | 3602M | 1932M | 1602M |
| Cash And Equivalents | 3577M | 3482M | 3602M | 1932M | 1602M |
| Total Current Liabilities | 3167M | 1797M | 2170M | 1806M | 1223M |
| Current Deferred Revenue | - | - | 1016M | 950M | 35M |
| Net Debt | 4513M | 3261M | 3760M | 4679M | 4850M |
| Short Term Debt | 1352M | 0M | 604M | 500M | 9M |
| Short Long Term Debt | 1352M | - | 604M | 500M | 9M |
| Short Long Term Debt Total | 8090M | 6743M | 7362M | 6611M | 6452M |
| Other Stockholder Equity | -3451M | -1884M | -1165M | -998M | -461M |
| Property Plant Equipment | 2753M | 2422M | 2202M | 1940M | 1658M |
| Total Current Assets | 7506M | 6930M | 6611M | 4748M | 4399M |
| Long Term Investments | - | - | - | 26M | 8M |
| Short Term Investments | - | - | - | 0M | 99M |
| Net Receivables | 1215M | 1133M | 1013M | 1086M | 1036M |
| Long Term Debt | 6552M | 6592M | 6595M | 5947M | 6443M |
| Inventory | 2345M | 1923M | 1628M | 1410M | 1391M |
| Accounts Payable | 405M | 436M | 457M | 301M | 313M |
| Accumulated Other Comprehensive Income | -817M | -764M | -730M | -726M | -629M |
| Non Currrent Assets Other | 147M | 111M | 106M | 98M | 94M |
| Non Current Assets Total | 7419M | 6970M | 6998M | 6797M | 6378M |
| Capital Lease Obligations | 186M | 151M | 163M | 164M | - |
| Long Term Debt Total | 6552M | 6592M | 6595M | 5947M | 6443M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -883M | 32M | -27M | 138M | 28M |
| Total Cashflows From Investing Activities | -883M | -458M | -572M | -504M | -2259M |
| Total Cash From Financing Activities | -904M | -1862M | 123M | -951M | 533M |
| Net Income | 2111M | 2034M | 1636M | 1500M | 1424M |
| Change In Cash | 96M | -119M | 1670M | 332M | 38M |
| Begin Period Cash Flow | 3485M | 3604M | 1934M | 1602M | 1564M |
| End Period Cash Flow | 3581M | 3485M | 3604M | 1934M | 1602M |
| Total Cash From Operating Activities | 1912M | 2213M | 2126M | 1795M | 1790M |
| Depreciation | 465M | 448M | 441M | 412M | 308M |
| Other Cashflows From Investing Activities | -311M | -13M | -92M | -182M | -1949M |
| Dividends Paid | -611M | -474M | -380M | -314M | 243M |
| Change To Inventory | -486M | -366M | -346M | -104M | 61M |
| Sale Purchase Of Stock | -1594M | -743M | -250M | -626M | -698M |
| Other Cashflows From Financing Activities | 1311M | -6M | 9M | -11M | 1474M |
| Capital Expenditures | 586M | 477M | 453M | 460M | 338M |
| Change In Working Capital | -699M | -343M | -85M | -151M | 112M |
| Other Non Cash Items | 259M | 96M | 137M | 46M | 5M |
| Free Cash Flow | 1326M | 1736M | 1673M | 1335M | 1452M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 11 months ago | 12989133 |
| 2. | Vanguard Institutional 500 Index Trust | 11 months ago | 11219541 |
| 3. | Capital Group Growth Fnd of Amer Comp | 1 year ago | 6117067 |
| 4. | American Funds Growth Fund of Amer A | 1 year ago | 6117067 |
| 5. | American Funds New Perspective A | 1 year ago | 5386453 |
| 6. | Capital Group New Perspective Comp | 1 year ago | 5386453 |
| 7. | Fidelity® 500 Index | 1 year ago | 5329851 |
| 8. | SPDR® S&P 500 ETF Trust | 11 months ago | 5220890 |
| 9. | iShares Core S&P 500 ETF | 11 months ago | 4536753 |
| 10. | Vanguard Health Care Inv | 1 year ago | 4530082 |
| 11. | Capital Group AMCAP Composite | 1 year ago | 4026471 |
| 12. | VA CollegeAmerica Amcap 529A | 1 year ago | 4026471 |
| 13. | Vanguard Growth Index Investor | 11 months ago | 3649513 |
| 14. | Health Care Select Sector SPDR® ETF | 11 months ago | 3558276 |
| 15. | AllianceBernstein US L/C Growth Eqty MF | 1 year ago | 3187516 |
| 16. | Vanguard Institutional Index I | 11 months ago | 3067884 |
| 17. | AB Large Cap Growth A | 1 year ago | 3033687 |
| 18. | American Funds American Mutual A | 1 year ago | 2943079 |
| 19. | Capital Group American Mutual Comp | 1 year ago | 2943079 |
| 20. | Vanguard Dividend Appreciation ETF | 11 months ago | 2651311 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Group Inc | 1 year ago | 39798489 |
| 2. | BlackRock Inc | 1 year ago | 36466414 |
| 3. | State Street Corporation | 1 year ago | 18970602 |
| 4. | State Farm Mutual Automobile Ins Co | 1 year ago | 17134819 |
| 5. | Capital Research & Mgmt Co - Division 3 | 1 year ago | 15105417 |
| 6. | AllianceBernstein L.P. | 1 year ago | 14500838 |
| 7. | Wellington Management Company LLP | 1 year ago | 12344692 |
| 8. | Morgan Stanley - Brokerage Accounts | 1 year ago | 12269454 |
| 9. | Bank of America Corp | 1 year ago | 12250781 |
| 10. | T. Rowe Price Associates, Inc. | 1 year ago | 10472607 |
| 11. | Geode Capital Management, LLC | 1 year ago | 10025610 |
| 12. | Capital World Investors | 1 year ago | 9006360 |
| 13. | FMR Inc | 1 year ago | 8136774 |
| 14. | Nuveen Asset Management, LLC | 1 year ago | 6462383 |
| 15. | Northern Trust Corp | 1 year ago | 6143258 |
| 16. | Polen Capital | 1 year ago | 5163881 |
| 17. | Capital Research Global Investors | 1 year ago | 4107460 |
| 18. | Bank of New York Mellon Corp | 1 year ago | 3998989 |
| 19. | Massachusetts Financial Services Company | 1 year ago | 3720771 |
| 20. | Legal & General Group PLC | 1 year ago | 3501431 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
